Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Isofol Medical AB ( (SE:ISOFOL) ) is now available.
Isofol Medical AB has commenced a clinical phase Ib/II study for its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the efficacy of arfolitixorin as part of a 5-FU-based therapy, with the potential to optimize treatment outcomes and bring the drug closer to market, marking a significant milestone for the company.
More about Isofol Medical AB
Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company’s primary drug candidate, arfolitixorin, aims to enhance the effectiveness of first-line standard treatments for various solid tumors, with a current focus on colorectal cancer. Isofol Medical is listed on Nasdaq Stockholm.
YTD Price Performance: -15.76%
Technical Sentiment Signal: Buy
Current Market Cap: €27.86M
See more data about ISOFOL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue